While many correlative studies and new treatment avenues have highlighted FGFR2 as a potential target for gastric cancer, preclinical models have highlighted FGFR2b as a particularly attractive target due to its pro-tumorigenic functions and specificity. This evidence concerns the gene FGFR2 and gastric cancer.